A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 7, 2005, Pages 871-879

  Schwimmer, J B ^a   Middleton, M S ^b   Deutsch, R ^c   Lavine, J E ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; METFORMIN;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIVER BIOPSY; LIVER TOXICITY; MALE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; BLOOD GLUCOSE; CHILD; FATTY LIVER; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; PILOT PROJECTS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 16444378976     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02420.x     Document Type: Article

References (45)

1. Kimm SY, Obarzanek E. Childhood obesity: a new pandemic of the new millennium. Pediatrics 2002; 110: 1003-7.
2. Lavine JE, Schwimmer JB. Pediatric non-alcoholic steatohepatitis. In: Farrell, G. George, J. Hall, P. McCollough, A. eds. Non-alcoholic Steatohepatitis. Oxford, England: Blackwell Publishing 2004; 229-40.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
4. Molleston JP, White F, Teckman J, Fitzgerald JF. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol 2002; 97: 2460-2.
5. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-25.
6. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143: 500-5.
7. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-4.
8. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-25.
9. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003; 38: 434-40.
10. Jones KL, Arslanian S, Peterokova VA, Park J-S, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002; 25: 89-94.
11. Schwimmer JB, Behling C, Deutsch R, Newbury R, Lavine JE. Gender, race, and obesity determine differences in children with pediatric versus adult-type NASH histology. Gastroenterology 2004; 126: A682.
12. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107: E55.
13. Krauss RM, Eckel RH, Howard B, et al. AHA Dietary Guidelines: revision 2000. A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000; 102: 2284-99.
14. Babich MM, Pike I, Shiffman ML. Metformin-induced acute hepatitis. Am J Med 1998; 104: 490-2.
15. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999; 22: 925-7.
16. Dietz WH, Robinson TN. Use of the body mass index (BMI) as a measure of overweight in children and adolescents. J Pediatr 1998; 132: 191-3.
17. Dietz WH, Bellizzi MC. Introduction: the use of body mass index to assess obesity in children. Am J Clin Nutr 1999; 70: 123S-5S.
18. Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 1985; 41: 810-7.
19. Nguyen TT, Keil MF, Russell DL, et al. Relation of acanthosis nigricans to hyperinsulinemia and insulin sensitivity in overweight African American and white children. J Pediatr 2001; 138: 474-80.
20. Burke JP, Hale DE, Hazuda HP, Stern MP. A quantitative scale of acanthosis nigricans. Diabetes Care 1999; 22: 1655-9.
21. Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 1994; 12: 487-95.
22. Longo R, Pollesello P, Ricci C, et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995; 5: 281-5.
23. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997; 100: 1166-73.
24. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-10.
25. Hrebicek J, Janout V, Malincikova J, Horakova D, Cizek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab 2002; 87: 144-7.
26. Varni JW, Seid M, Rode CA. The PedsQL™: measurement model for the pediatric quality of life inventory. Med Care 1999; 37: 126-39.
27. Varni JW, Seid M, Kurtin PS. The PedsQL™ 4.0: reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001; 39: 800-12.
28. Schwimmer JB, Burwinkle TM, Varni JW. Health-related quality of life of severely obese children and adolescents. JAMA 2003; 289: 1813-9.
29. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001; 29: 160-9.
30. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001; 50: 1457-61.
31. Schwimmer JB, McGreal N, Deutsch R, Finegold M, Lavine JE. The influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005 (in press).
32. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-44.
33. Nair S, Dichl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-8.
34. Tiikkainen M, Hakkinen A-M, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169-76.
35. Tiikkainen M, Bergholm R, Vehkavaara S, et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003; 52: 701-7.
36. Koo S-H, Dutcher AK, Towle HC. Glucose and insulin function through two distinct transcription factors to stimulate expression of lipogenic enzyme genes in liver. J Biol Chem 2001; 276: 9437-45.
37. Ferré P, Foretz M, Azzout-Marniche D, Bécard D, Foufelle F. Sterol regulatory element-binding protein 1c mediates insulin action on hepatic gene expression. Biochem Soc Trans 2001; 29: 547-52.
38. Yamashita H, Takenoshita M, Sakurai M, et al. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. PNAS 2001; 98: 9116-21.
39. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-52.
40. Nguyen-Duy T-B, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat and liver fat are independent predictors of metabolic risk factors in men. Am J Physiol Endocrinol Metab 2003; 284: E1065-71.
41. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6: 998-1003.
42. Magalotti D, Marchesini G, Ramilli S, Berzigotti A, Blanchi G, Zoli M. Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment A pilot study. Dig Liver Dis 2004; 36: 406-11.
43. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125: 239-41.
44. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136: 734-8.
45. Lavine JE, Schwimmer JB. Pediatric initiatives within the nonalcoholic steatohepatitis - clinical research network (NASH CRN). JPGN 2003; 37: 220-1.